Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALVOVAR: Weekly dose-dense carboplatin-paclitaxel in poor-prognosis ovarian cancer
jRCTs031240276Phase 3Recruiting
- Sponsor
- Arcagy-Gineco
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel and bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoints: Late complete debulking surgery rate after 3 cycles and Overall survival. Started Nov 2024; status: recruiting.
02
Drugs
carboplatinpaclitaxelbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCTs031240276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240276.